Clinical Case: 24-Year-Old Woman with Acute Lower Abdominal Pain, Fever, and Cervical Motion Tenderness — PID Diagnosis and CDC Regimens for NEET PG

NEET PG PID case: 24-yo woman with lower abdominal pain, fever, dyspareunia, CMT, mucopurulent discharge — CDC criteria, differentials, regimens, Fitz-Hugh-Curtis, MCQ traps.

Pelvic examination: Speculum reveals a small amount of mucopurulent yellow discharge at the cervical os; the cervix appears erythematous and friable, bleeding lightly when gently swabbed. Bimanual exam — cervical motion tenderness elicits a strong wince and "extreme tenderness" reported, uterine tenderness on bimanual fundic palpation, bilateral adnexal tenderness without a definite mass. No ovarian fullness palpable. Posterior fornix non-bulging. No discrete palpable adnexal mass.

Urine pregnancy test: negative.

The on-call OBG registrar starts an immediate stepwise workup while empirical antibiotics are prepared.

ABCD assessment and immediate workflow

A — Airway: Patent. GCS 15. No compromise.

B — Breathing: RR 22 (mild tachypnea, likely from pain and fever). SpO2 99 percent on room air. Chest clear.

C — Circulation: HR 112, BP 108/68 (mild tachycardia from fever and pain; not septic shock). Two large-bore IVs (18G). Crystalloid 500 mL bolus and reassess. Send labs.

D — Disability/Dextrose: GCS 15, glucose 96. Pain 8/10 — IV paracetamol 1 g and IV diclofenac 75 mg (not contraindicated; no ulcer, no renal impairment, no bleeding diathesis), titrated opioid (tramadol or low-dose morphine) if inadequate.

Initial workflow checklist:

• Urine HCG — must rule out pregnancy in any reproductive-age woman with abdominal pain
• Bedside transvaginal USG if available — assess for tubo-ovarian abscess, free fluid, ovarian torsion, ectopic
• Speculum and bimanual exam — establishes CMT, mucopurulent cervicitis
• Endocervical NAAT for Chlamydia trachomatis and Neisseria gonorrhoeae (gold standard)
• Endocervical culture for gonococcus (susceptibility) — increasingly relevant with rising AMR
• Saline wet mount of vaginal fluid — leukocytes (WBC >1 per epithelial cell supports cervicitis), trichomonads, clue cells
• HIV test (point-of-care or rapid), VDRL/RPR, hepatitis B surface antigen — universal STI workup
• CBC, CRP, ESR — leukocytosis and elevated inflammatory markers support but are not required
• Liver function tests if RUQ pain to assess Fitz-Hugh-Curtis vs cholecystitis vs hepatitis
• Lactate if any concern for sepsis
• Blood cultures × 2 if febrile and admitting for IV therapy

Initial labs:

• CBC: WBC 13,400 with 78 percent neutrophils, Hb 12.6, platelets 312,000
• CRP: 84 mg/L (raised); ESR: 42 mm/hr
• Urinalysis: mild leukocyturia (likely contamination from cervicitis), no nitrites, no hematuria
• Liver enzymes: AST 28, ALT 22, ALP 78, bilirubin 0.6 — normal
• Beta-hCG: negative
• HIV, HBsAg, VDRL: negative (rapid)
• Wet mount: abundant leukocytes, no clue cells, no trichomonads
• Endocervical NAAT: sent — result expected in 24-48 hours
• TVS: mildly echogenic dilated bilateral fallopian tubes with thickened walls (hydrosalpinx-like pattern); small amount of fluid in the cul-de-sac; no discrete tubo-ovarian abscess; ovaries normal in size with appropriate follicular pattern; uterus normal

The picture fits PID. Treatment is started empirically before NAAT results.

Diagnostic criteria — CDC minimum, additional, and specific

CDC sets a deliberately low threshold for empirical PID treatment because the cost of missed diagnosis is reproductive morbidity.

CDC minimum criteria (start empirical treatment if any one is present)

In a sexually active young woman with pelvic or lower abdominal pain and no other identifiable cause:

1. Cervical motion tenderness ("chandelier sign" — patient jumps off the examination table)
2. Uterine tenderness on bimanual examination
3. Adnexal tenderness on bimanual examination

Additional criteria (increase specificity; not required)

• Oral temperature >38.3 C
• Abnormal mucopurulent cervical discharge or friable cervix
• Abundant white blood cells on saline microscopy of vaginal fluid
• Raised ESR or CRP
• Laboratory documentation of cervical N. gonorrhoeae or C. trachomatis infection

Most specific criteria (definitive but rarely needed for clinical diagnosis)

• Endometrial biopsy with histopathologic evidence of endometritis
• Transvaginal ultrasound or MRI showing thickened, fluid-filled tubes ± free pelvic fluid ± tubo-ovarian abscess
• Laparoscopy with visible findings of salpingitis (PID gold standard but invasive)

Our patient meets all three minimum criteria plus mucopurulent cervicitis, fever, raised CRP/ESR, and supportive USG findings. Diagnosis is confirmed clinically.

Differential diagnosis — the dangerous mimics

Three categories of differential need to be excluded.

Surgical emergencies that mimic PID

Genitourinary mimics

• Acute cystitis / pyelonephritis — dysuria predominant, costovertebral angle tenderness, urine culture positive
• Renal colic — flank-to-groin pain, hematuria, calculus on USG/CT

Gastrointestinal mimics

• IBS exacerbation, diverticulitis, mesenteric adenitis, infectious gastroenteritis — careful history, GI predominant features

The cardinal rule: any woman of reproductive age with abdominal pain gets a urine pregnancy test BEFORE imaging or analgesia. Ectopic pregnancy is a life-threatening miss.

Microbiology — what causes PID

PID is a polymicrobial ascending infection. The pathogen mix:

The current empirical regimens are designed to cover gonorrhea, chlamydia, anaerobes, and BV-associated organisms simultaneously.

Diagnosis

Acute pelvic inflammatory disease, moderate severity, in a 24-year-old sexually active nulligravid woman with three lifetime partners, presumed gonococcal-chlamydial-anaerobic etiology pending NAAT results, no tubo-ovarian abscess on TVS, urine pregnancy negative, no surgical emergency, hemodynamically stable — eligible for outpatient CDC regimen with 72-hour reassessment.

Management — the CDC regimens

CDC outpatient regimen (2021 guidelines)

The standard outpatient regimen for moderate PID:

• Ceftriaxone 500 mg IM single dose (1 g IM if weight ≥150 kg) — covers gonorrhea
• Doxycycline 100 mg PO twice daily for 14 days — covers chlamydia and Mycoplasma genitalium
• Metronidazole 500 mg PO twice daily for 14 days — covers anaerobes and BV-associated organisms

Alternative if cephalosporin allergy (severe IgE-mediated): IM gentamicin plus oral doxycycline plus metronidazole, after consultation; many centres prefer hospital admission in severe penicillin/cephalosporin allergy.

CDC inpatient regimens

Indications for inpatient management:

• Surgical emergency (ectopic, appendicitis) cannot be excluded
• Pregnancy
• Failure of oral therapy at 72 hours
• Inability to follow / tolerate oral regimen
• Severe illness — high fever >39 C, vomiting, sepsis
• Tubo-ovarian abscess on imaging
• Immunosuppression (HIV with low CD4)
• Adolescent — selected cases

Regimen A (parenteral cephalosporin + doxycycline):

• Cefoxitin 2 g IV every 6 hours OR cefotetan 2 g IV every 12 hours
• PLUS doxycycline 100 mg PO/IV every 12 hours

Regimen B (clindamycin + gentamicin):

• Clindamycin 900 mg IV every 8 hours
• PLUS gentamicin 2 mg/kg loading then 1.5 mg/kg every 8 hours (or once-daily 5-7 mg/kg)

Switch to oral after 24-48 hours of clinical improvement: doxycycline 100 mg BD ± metronidazole 500 mg BD, total 14 days.

Tubo-ovarian abscess

TOA on imaging mandates inpatient management with parenteral broad-spectrum antibiotics. Add metronidazole or clindamycin to provide superior anaerobic coverage. Drainage (percutaneous USG-guided or laparoscopic) is indicated for:

• Abscess >9 cm (some guidelines >5-7 cm)
• Failure to respond at 48-72 hours of antibiotics
• Suspected rupture (peritonitis, sepsis)
• Persistent fever despite antibiotics

Partner treatment

All sexual partners within 60 days (or the most recent partner if no contact in 60 days) should be:

• Examined and tested for gonorrhea, chlamydia, HIV, syphilis
• Treated empirically for gonorrhea and chlamydia regardless of their symptoms or test results
• Standard partner regimen: ceftriaxone 500 mg IM + doxycycline 100 mg PO BD × 7 days

Expedited partner therapy (EPT) — providing prescriptions or medications for partners without formal evaluation — is endorsed by CDC where legal; in India, partner referral to clinic remains the standard.

Patient and partners must abstain from intercourse until both have completed therapy and are asymptomatic.

Special situations

• Pregnancy: all pregnant women with PID are admitted; doxycycline contraindicated — replace with azithromycin; clindamycin and ceftriaxone are pregnancy-compatible
• IUD in situ: does NOT mandate removal in mild-to-moderate PID; close clinical follow-up with antibiotics; if no improvement at 48-72 hours, consider removal
• HIV co-infection: CD4 monitoring; same regimens; may need longer duration; higher TOA risk
• Postpartum endometritis: different organisms (anaerobes, GBS, enteric); broader regimen (clindamycin + gentamicin or piperacillin-tazobactam)

Our patient's management

Hemodynamically stable, no TOA, ambulatory, tolerating oral fluids, no surgical emergency, mild dehydration corrected with IV crystalloid in ED. Outpatient CDC regimen initiated:

• Ceftriaxone 500 mg IM administered in ED
• Doxycycline 100 mg PO BD for 14 days
• Metronidazole 500 mg PO BD for 14 days

Patient counselling:

• Take all 14 days of antibiotics even if symptoms resolve
• Avoid alcohol while on metronidazole (disulfiram reaction)
• Doxycycline — take with full glass of water, avoid lying down for 30 minutes (esophageal ulceration), avoid sun, no antacids/dairy within 2 hours
• Abstain from intercourse until both partners complete therapy
• Partner notification — provide expedited referral
• Return immediately if vomiting, worsening pain, high fever, or unable to tolerate medication
• Follow-up at 72 hours and at 14 days

At 72-hour follow-up: afebrile, pain reduced to 3/10, tolerating oral meds, no new symptoms. NAAT returns positive for both Chlamydia trachomatis and Neisseria gonorrhoeae. Treatment continued. Partner contacted by health worker, treated with same regimen.

At 14-day follow-up: symptom-free. Test of cure NAAT recommended at 3 months due to high reinfection risk; routine repeat NAAT at 1 month is otherwise unnecessary unless symptoms persist.

Fitz-Hugh-Curtis syndrome

Right upper quadrant tenderness in PID — present mildly in our patient — should prompt consideration of Fitz-Hugh-Curtis (FHC) syndrome, perihepatitis from intra-peritoneal spread of C. trachomatis (more common, ~70 percent of FHC cases) or N. gonorrhoeae.

Clinical features:

• Pleuritic right hypochondrial pain, often the dominant symptom
• May be mistaken for cholecystitis, pleurisy, or hepatitis
• Liver enzymes typically NORMAL (the inflammation is capsular, not hepatocellular)

Diagnosis:

• Clinical context of PID + RUQ pain
• Imaging: non-specific perihepatic stranding on CT, occasionally early hepatic capsular enhancement
• Definitive diagnosis: laparoscopy showing classic "violin-string" fibrinous adhesions between the liver capsule and the anterior abdominal wall

Treatment: same as PID — antibiotics resolve perihepatitis. Persistent adhesions causing chronic pain rarely require lysis.

Complications and long-term sequelae

PID is a major preventable cause of female reproductive morbidity:

Treatment within 48 hours of symptom onset halves the long-term infertility risk compared with treatment delayed beyond 72 hours. This is why CDC emphasises empirical treatment over diagnostic confirmation.

India-specific considerations

NEET PG vignettes increasingly weave in India-specific public-health context.

National framework. Reproductive Tract Infection (RTI) and Sexually Transmitted Infection (STI) services are integrated under the National Health Mission through the National AIDS Control Programme (NACP) with Designated STI/RTI Clinics (also called Suraksha clinics) at district hospitals and many CHC level. Free syndromic management and partner-notification kits are provided.

Syndromic management. WHO-endorsed syndromic kits (used in Indian PHCs/CHCs where lab confirmation is not feasible) include:

• Kit 1 (urethral discharge in men, cervicitis): azithromycin 1 g + cefixime 400 mg
• Kit 2 (vaginal discharge): secnidazole + fluconazole
• Kit 6 (PID): ceftriaxone 500 mg + doxycycline + metronidazole — closely matches CDC regimen

Cultural and access considerations. Stigma around STI evaluation, partner notification challenges, and limited contraceptive use among young unmarried women contribute to delayed presentation. ASHA workers and ANM-led counselling, expanded condom social marketing, and HPV vaccination integration into immunisation programmes are shifting the landscape.

Antimicrobial resistance. Rising gonococcal resistance to fluoroquinolones (now >90 percent in many Indian cities) means fluoroquinolone-based PID regimens are no longer first-line — ceftriaxone has replaced ofloxacin/levofloxacin in updated NACP guidelines. Cephalosporin-resistant gonorrhea is emerging.

Tuberculous PID. Genital TB is a non-trivial cause of chronic PID and infertility in India, particularly with chronic adnexal masses, infertility workup with bilateral tubal block on HSG, and characteristic "beaded tube" appearance. Endometrial biopsy with culture and AFB / GeneXpert may be needed. Treated with standard antitubercular regimen.

How NEET PG tests PID

Eight recurring patterns. Recognise the pattern and the question collapses.

Pattern 1 — The minimum criteria question: Vignette gives sexually active young woman with lower abdominal pain. Asked about CDC minimum criteria. Answer: CMT, uterine tenderness, OR adnexal tenderness — any one, in absence of another cause.

Pattern 2 — The first-line investigation question: Reproductive-age woman with abdominal pain and fever. First test? Urine HCG (rule out ectopic). Trap: "send NAAT first" — wrong; NAAT result takes 24-48 hr and treatment is empirical.

Pattern 3 — The CDC regimen question: First-line outpatient PID? Ceftriaxone 500 mg IM + doxycycline 100 mg BD × 14 d + metronidazole 500 mg BD × 14 d. Trap: regimens with ofloxacin alone (outdated due to gonococcal resistance) or no metronidazole (misses anaerobes).

Pattern 4 — The admission question: When to hospitalise? Pregnancy, oral failure at 72 hr, severe illness/sepsis, TOA, surgical emergency cannot be excluded, immunosuppression, intolerance of oral regimen.

Pattern 5 — The Fitz-Hugh-Curtis question: Young woman with PID and acute pleuritic RUQ pain with normal LFTs. Diagnosis? Fitz-Hugh-Curtis syndrome (perihepatitis from chlamydia). Treatment? Same as PID. Diagnostic finding on laparoscopy? "Violin-string" perihepatic adhesions.

Pattern 6 — The TOA management question: Patient with PID and a 7 cm adnexal abscess, persistent fever despite 72 h IV antibiotics. Best management? Percutaneous USG-guided drainage (or laparoscopic if not feasible).

Pattern 7 — The partner management question: Partner of a woman with PID. Best management? Treat empirically for gonorrhea and chlamydia regardless of partner's symptoms or test results (any partner within 60 days).

Pattern 8 — The complication question: PID episode → infertility risk? 10 percent after 1 episode, 25 percent after 2, 40-50 percent after 3. Ectopic pregnancy risk? 6-10 fold increased.

High-yield one-liners:

• CDC minimum criteria: CMT, uterine tenderness, or adnexal tenderness — any one, treat empirically
• Always do urine HCG before any abdominal pain workup in reproductive-age women
• Outpatient: ceftriaxone 500 mg IM + doxycycline 14 d + metronidazole 14 d
• Inpatient: cefoxitin + doxycycline OR clindamycin + gentamicin
• Treat all partners within 60 days for gonorrhea and chlamydia
• Fitz-Hugh-Curtis = perihepatitis with violin-string adhesions; mostly chlamydia
• Infertility 10/25/40 percent after 1/2/3 episodes
• IUD in mild-moderate PID — leave in, treat; remove if no improvement at 72 hr
• TOA >9 cm or no response at 48-72 hr → drainage
• Pregnancy + PID = always admit; doxycycline contraindicated; use azithromycin instead
• Genital TB is a significant chronic PID/infertility differential in India
• NACP Kit 6 = syndromic PID kit (ceftriaxone + doxycycline + metronidazole)

Frequently Asked Questions

What are the CDC minimum diagnostic criteria for pelvic inflammatory disease?

CDC recommends empirical PID treatment in any sexually active young woman with pelvic or lower abdominal pain who has at least one of the three minimum criteria on bimanual examination: cervical motion tenderness, uterine tenderness, or adnexal tenderness. The diagnostic threshold is intentionally low because untreated PID causes infertility (10 percent after one episode, 40 percent after three), ectopic pregnancy, and chronic pelvic pain. Additional supportive criteria — fever over 38.3 C, mucopurulent cervical discharge, leukocytes on saline microscopy of vaginal fluid, raised ESR or CRP, and laboratory documentation of cervical N. gonorrhoeae or C. trachomatis — increase specificity but are not required to start treatment.

What is the recommended CDC outpatient regimen for pelvic inflammatory disease?

The 2021 CDC outpatient PID regimen is ceftriaxone 500 mg IM single dose (or 1 g IM if weight 150 kg or more) plus doxycycline 100 mg PO twice daily for 14 days plus metronidazole 500 mg PO twice daily for 14 days. The cephalosporin covers Neisseria gonorrhoeae, doxycycline covers Chlamydia trachomatis and Mycoplasma genitalium, and metronidazole covers anaerobes and bacterial vaginosis-associated pathogens that frequently coexist. Reassess at 72 hours — if no improvement, hospitalise for IV therapy and re-evaluate for tubo-ovarian abscess or alternative diagnoses. All recent sexual partners within 60 days require empirical treatment for gonorrhea and chlamydia.

When is hospital admission required for pelvic inflammatory disease?

CDC criteria for inpatient PID management: surgical emergency cannot be excluded (ectopic pregnancy, appendicitis); pregnancy; failure to respond clinically to oral antimicrobial therapy at 72 hours; inability to follow or tolerate an outpatient oral regimen; severe illness with nausea, vomiting, or high fever over 39 C; tubo-ovarian abscess on imaging; immunosuppression including HIV with low CD4. Adolescents may benefit from inpatient admission in selected cases for adherence and partner-notification support. Inpatient regimens include cefoxitin 2 g IV every 6 hours plus doxycycline 100 mg PO/IV every 12 hours, OR clindamycin 900 mg IV every 8 hours plus gentamicin 2 mg/kg loading then 1.5 mg/kg every 8 hours.

What is Fitz-Hugh-Curtis syndrome and how does it present?

Fitz-Hugh-Curtis syndrome is perihepatitis caused by ascending pelvic infection from Chlamydia trachomatis (more common) or Neisseria gonorrhoeae spreading via the paracolic gutters to the liver capsule. It presents in 4-15 percent of women with PID with sudden right upper quadrant pain, often pleuritic and worsened by deep breathing or movement, that may be more prominent than the pelvic symptoms. Examination reveals right hypochondrial tenderness with normal liver enzymes typically; the diagnosis is often missed and labelled as cholecystitis or pleurisy. Imaging may show non-specific perihepatic stranding; laparoscopy reveals classic 'violin-string' fibrinous adhesions between the liver capsule and the anterior abdominal wall. Treatment is the same as PID — antibiotics resolve perihepatitis.

What are the long-term complications of pelvic inflammatory disease and how can they be prevented?

PID is a leading cause of female reproductive morbidity. Major complications: tubal-factor infertility (10 percent risk after one PID episode, 25 percent after two, 40-50 percent after three); ectopic pregnancy (6-10 fold increased risk due to tubal scarring); chronic pelvic pain (30 percent at 6 months); tubo-ovarian abscess (acute), Fitz-Hugh-Curtis perihepatitis, and chronic salpingitis. Prevention strategies: prompt treatment within 48 hours of symptom onset (delay over 72 hours doubles infertility risk), partner notification and treatment to prevent reinfection, screening of asymptomatic high-risk women under 25 for chlamydia annually, condom use, and avoiding intrauterine instrumentation in women with active cervicitis.

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: May 2026